The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy
Abstract
OBJECTIVE: The protein kinase C (PKC) agonist bryostatin-1 has shown significant ex-vivo potency to revert HIV-1 latency, compared with other latency reversing agents (LRA). The safety of this candidate LRA remains to be proven in treated HIV-1-infected patients. METHODS: In this pilot, double-blind phase I clinical-trial (NCT 02269605), we included aviraemic HIV-1-infected patients on triple antiretroviral therapy to evaluate the effects of two different single doses of bryostatin-1 (10 or 20 μg/m) compared with placebo. RESULTS: Twelve patients were included, four in each arm. Bryostatin-1 was well tolerated in all participants. Two patients in the 20 μg/m arm developed grade 1 headache and myalgia. No detectable increases of cell-associated unspliced (CA-US) HIV-1-RNA were observed in any study arm, nor differences in HIV-1 mRNA dynamics between arms (P = 0.44). The frequency of samples with low-level viraemia did not differ between arms and low-level viraemia did not correlate with CA-US HIV-1-RNA levels (P = 0.676). No changes were detected on protein kinase C (PKC) activity and in biomarkers of inflammation (sCD14 and interleukin-6) in any study arm. After the single dose of bryostatin-1, plasma concentrations were under detection limits in all the patients in the 10 μg/m arm, and below 50 pg/ml (0.05 nmol/l) in those in the 20 μg/m arm. CONCLUSION: Bryostatin-1 was safe at the single doses administered. However, the drug did not show any effect on PKC activity or on the transcription of latent HIV, probably due to low plasma concentrations. This study will inform next trials aimed at assessing higher doses, multiple dosing schedules or combination studies with synergistic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
Finzi, D., Hermankova, M., Pierson, T., Carruth, L. M., Buck, C., Chaisson, R. E., Quinn, T. C., Chadwick, K., Margolick, J., Brookmeyer, R., et al. (1997) · Science · doi:10.1126/science.278.5341.1295 · Cited by 3,098
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
Chun, T.-W., Carruth, L., Finzi, D., Shen, X., DiGiuseppe, J. A., Taylor, H., Hermankova, M., Chadwick, K., Margolick, J., Quinn, T. C., et al. (1997) · Nature · doi:10.1038/387183a0 · Cited by 2,050
Cited by
Getting the “Kill” into “Shock and Kill”: Strategies to Eliminate Latent HIV
Kim, Y., Anderson, J. L., & Lewin, S. R. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2017.12.004 · Cited by 414
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021
Deeks, S. G., Archin, N., Cannon, P., Collins, S., Jones, R. B., de Jong, M. A. W. P., Lambotte, O., Lamplough, R., Ndung’u, T., Sugarman, J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01590-5 · Cited by 377
Targeting the Latent Reservoir for HIV-1
Sengupta, S., & Siliciano, R. F. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.030 · Cited by 340
Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo
Nixon, C. C., Mavigner, M., Sampey, G. C., Brooks, A. D., Spagnuolo, R. A., Irlbeck, D. M., Mattingly, C., Ho, P. T., Schoof, N., Cammon, C. G., et al. (2020) · Nature · doi:10.1038/s41586-020-1951-3 · Cited by 299
HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment
Singh, K. P., Crane, M., Audsley, J., Avihingsanon, A., Sasadeusz, J., & Lewin, S. R. (2017) · AIDS · doi:10.1097/qad.0000000000001574 · Cited by 268
Metadata
- Authors
- Gutiérrez, C., Serrano-Villar, S., Madrid-Elena, N., Pérez-Elías, M. J., Martín, M. E., Barbas, C., Ruipérez, J., Muñoz, E., Muñoz-Fernández, M. A., Castor, T., & Moreno, S.
- Venue
- AIDS
- Published
- 2016-06-01
- Volume
- 30
- Issue
- 9
- Pages
- 1385-1392
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2417209002
- Cited by
- 203
- References
- 2
- FWCI
- 14.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. https://app.cochat.ai/papers/10.1097/qad.0000000000001064
- The paper
- Gutiérrez, C., Serrano-Villar, S., Madrid-Elena, N., Pérez-Elías, M. J., Martín, M. E., Barbas, C., Ruipérez, J., Muñoz, E., Muñoz-Fernández, M. A., Castor, T., & Moreno, S. (2016). Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. AIDS. https://doi.org/10.1097/qad.0000000000001064
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.